Enter inventor name

David Grierson

This inventor holds 18 USPTO granted patents and 3 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Institut Curie, National Institute of Health and Medical Research. Active years: 2002-2020.

USPTO Granted Patents = 18

% Patents Active = 44.4

EPO Patents = 3

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 65(Granted Patents)

Location History:

Buc, FR (2002 - 2006)
Versaillies, FR (2010)
Versailles, FR (2004 - 2014)
Vancouver, CA (US) (2016)
Vancouver, CA (2010 - 2020)

Company Filing History:

14 out of 5,383

Centre National De La Recherche Scientifique

National Institute of Health and Medical Research

Universitè De Montpellier

patents

6. 2 out of 37

Université Montpellier 2 Sciences Et Techniques

patents

7. 2 out of 42

Université Pierre Et Marie Curie (Paris Vi)

patents

8. 1 out of 5

Centre for Drug Research and Development

patents

9. 1 out of 8,801

Commissariat a L'energie Atomique Et Aux Energies Alternatives

The University of British Columbia

patents

12. 1 out of 1

The University of Montpellier 2 Science and Techniques

patent

13. 2 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2020

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10654813 - Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies (2020-05-19),

2. 10196345 - MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof (2019-02-05),

3. 10130595 - Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies (2018-11-20),

4. 9233931 - Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies (2016-01-12),

5. 8895726 - Compounds derived from indole and pharmaceutical compositions containing them (2014-11-25),

6. 8658659 - Substituted oxazole derivatives and their use as tyrosine kinase inhibitors (2014-02-25),

7. 8604063 - Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies (2013-12-10),

8. 8313731 - [object Object] (2012-11-20),

9. 8110591 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors (2012-02-07),

10. 7989467 - Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process (2011-08-02),

11. 7981400 - Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors (2011-07-19),

12. 7728128 - Dibenzo[c,h][1,5]naphthyridines and their use as DNA probes (2010-06-01),

13. 7718676 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors (2010-05-18),

14. 7718601 - [object Object] (2010-05-18),

15. 7371742 - Porphyrin derivatives for photodynamic therapy (2008-05-13),

Title: David Grierson - Innovative Inventor from Versailles, FR

Introduction: David Grierson is a renowned inventor based in Versailles, France, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: David Grierson holds several patents in the areas of renewable energy, artificial intelligence, and biotechnology, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a career spanning over two decades, David Grierson has worked with leading research institutions and universities to develop cutting-edge technologies that have revolutionized industries worldwide.

Collaborations: Throughout his career, David Grierson has collaborated with top companies, banks, and innovative startups to bring his inventions to the market, solidifying his reputation as a visionary inventor.

Conclusion: David Grierson's passion for innovation and his relentless pursuit of excellence have established him as a key figure in the world of inventions, inspiring the next generation of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]